NASDAQ
08.08.25 | 18:29
0,385 US-Dollar
+4,14 % +0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Athira Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| Do | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Athira Pharma, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.05. | Athira Pharma, Inc.: Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit | 1 | GlobeNewswire (USA) | ||
| 09.05. | Athira Pharma GAAP EPS of -$0.23 beats by $0.01 | 2 | Seeking Alpha | ||
| 09.05. | Athira Pharma, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 09.05. | Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | 373 | GlobeNewswire (Europe) | Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing... ► Artikel lesen | |
| 09.05. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.02. | Athira Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 17 | SEC Filings | ||
| 06.12.24 | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 472 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 07.11.24 | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 312 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 01.11.24 | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | 1.248 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,250 | 0,00 % | Palatin Technologies, Inc.: Palatin Announces 1-for-50 Reverse Stock Split | PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its... ► Artikel lesen | |
| BIOXXMED | 0,250 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,860 | +0,42 % | Ocugen sichert sich 20 Millionen US-Dollar über registrierte Direktplatzierung | ||
| INFLARX | 0,700 | +0,57 % | InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,880 | -6,38 % | Bio-Gate mit Verlust, Aktie stürzt ab | Bio-Gate hat die endgültigen Zahlen für 2024 vorgelegt. An der Börse kommen die Zahlen der Bilanz schlecht an: Die Bio-Gate Aktie notiert aktuell bei 0,82 Euro mit 20,39 Prozent im Minus. Das Unternehmen... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -2,96 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,307 | 0,00 % | Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders | - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart,... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,640 | -8,89 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Production of Fava Protein and Officially Launches FavaPro 90%+ Pure Plant Protein | Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,730 | +0,42 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) | There will be presentations on the latest positive progress from AIM's clinical program in pancreatic cancer, the positive therapeutic effects of AIM's drug Ampligen on multiple cancer types, and... ► Artikel lesen | |
| IMMUNIC | 0,740 | -1,20 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07.08.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |
ATHIRA PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,015 (+4,14 %) liegt der Kurs bei 0,385 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.